Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI).

Puy C, Ngo ATP, Pang J, Keshari RS, Hagen MW, Hinds MT, Gailani D, Gruber A, Lupu F, McCarty OJT.

Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1390-1401. doi: 10.1161/ATVBAHA.119.312619. Epub 2019 May 23.

PMID:
31242030
2.

A non-circulating pool of factor XI associated with glycosaminoglycans in mice.

Mohammed BM, Cheng Q, Matafonov A, Verhamme IM, Emsley J, McCrae KR, McCarty OJT, Gruber A, Gailani D.

J Thromb Haemost. 2019 May 24. doi: 10.1111/jth.14494. [Epub ahead of print]

PMID:
31125187
3.

Phenotype of ribonuclease 1 deficiency in mice.

Garnett ER, Lomax JE, Mohammed BM, Gailani D, Sheehan JP, Raines RT.

RNA. 2019 Aug;25(8):921-934. doi: 10.1261/rna.070433.119. Epub 2019 May 3.

PMID:
31053653
4.

Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and death.

Silasi R, Keshari RS, Lupu C, Van Rensburg WJ, Chaaban H, Regmi G, Shamanaev A, Shatzel JJ, Puy C, Lorentz CU, Tucker EI, Gailani D, Gruber A, McCarty OJT, Lupu F.

Blood Adv. 2019 Feb 26;3(4):658-669. doi: 10.1182/bloodadvances.2018029983.

5.

Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.

Lorentz CU, Verbout NG, Wallisch M, Hagen MW, Shatzel JJ, Olson SR, Puy C, Hinds MT, McCarty OJT, Gailani D, Gruber A, Tucker EI.

Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809. doi: 10.1161/ATVBAHA.118.312328.

PMID:
30700130
6.

A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.

Ivanov I, Matafonov A, Sun MF, Mohammed BM, Cheng Q, Dickeson SK, Kundu S, Verhamme IM, Gruber A, McCrae K, Gailani D.

Blood. 2019 Mar 7;133(10):1152-1163. doi: 10.1182/blood-2018-06-860270. Epub 2018 Dec 27.

PMID:
30591525
7.

Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo.

Zilberman-Rudenko J, Reitsma SE, Puy C, Rigg RA, Smith SA, Tucker EI, Silasi R, Merkulova A, McCrae KR, Maas C, Urbanus RT, Gailani D, Morrissey JH, Gruber A, Lupu F, Schmaier AH, McCarty OJT.

Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1748-1760. doi: 10.1161/ATVBAHA.118.311193.

PMID:
30354195
8.

Dilutional coagulopathy in pediatric scoliosis surgery: A single center report.

Baker CE, Marvi T, Austin TM, Payne S, Mignemi ME, Gailani D, Wheeler AP, Nguyen TT, Lovejoy SA, Martus JE, Mencio GA, Schoenecker JG.

Paediatr Anaesth. 2018 Nov;28(11):974-981. doi: 10.1111/pan.13488. Epub 2018 Oct 8.

PMID:
30295357
9.

Plasma contact factors as therapeutic targets.

Tillman BF, Gruber A, McCarty OJT, Gailani D.

Blood Rev. 2018 Nov;32(6):433-448. doi: 10.1016/j.blre.2018.04.001. Epub 2018 Apr 12. Review.

PMID:
30075986
10.

Factor XI promotes hemostasis in factor IX-deficient mice.

Mohammed BM, Cheng Q, Matafonov A, Monroe DM, Meijers JCM, Gailani D.

J Thromb Haemost. 2018 Oct;16(10):2044-2049. doi: 10.1111/jth.14243. Epub 2018 Aug 16.

PMID:
30007049
11.

Peptidoglycan induces disseminated intravascular coagulation in baboons through activation of both coagulation pathways.

Popescu NI, Silasi R, Keshari RS, Girton A, Burgett T, Zeerleder SS, Gailani D, Gruber A, Lupu F, Coggeshall KM.

Blood. 2018 Aug 23;132(8):849-860. doi: 10.1182/blood-2017-10-813618. Epub 2018 Jun 19.

12.

Factor XI and pulmonary infections.

Gailani D, Mohammed BM, Cheng Q.

Haemophilia. 2018 Jul;24(4):519-521. doi: 10.1111/hae.13503. Epub 2018 May 29. No abstract available.

13.

Factor XI contributes to myocardial ischemia-reperfusion injury in mice.

Lorentz CU, Verbout NG, Cao Z, Liu L, Hinds MT, McCarty OJT, Ivanov I, Tucker EI, Gailani D, Gruber A.

Blood Adv. 2018 Jan 23;2(2):85-88. doi: 10.1182/bloodadvances.2017004879. No abstract available.

14.

Activity of Factor XII-Locarno.

Mohammed BM, Ivanov I, Matafonov A, Emsley J, Gailani D.

Res Pract Thromb Haemost. 2018 Jan;2(1):168-173. doi: 10.1002/rth2.12054. Epub 2017 Nov 13.

15.

Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions.

Garland KS, Reitsma SE, Shirai T, Zilberman-Rudenko J, Tucker EI, Gailani D, Gruber A, McCarty OJT, Puy C.

Front Med (Lausanne). 2017 Dec 20;4:232. doi: 10.3389/fmed.2017.00232. eCollection 2017.

16.

An update on factor XI structure and function.

Mohammed BM, Matafonov A, Ivanov I, Sun MF, Cheng Q, Dickeson SK, Li C, Sun D, Verhamme IM, Emsley J, Gailani D.

Thromb Res. 2018 Jan;161:94-105. doi: 10.1016/j.thromres.2017.10.008. Epub 2017 Oct 10. Review.

17.

Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.

Tillman B, Gailani D.

Semin Thromb Hemost. 2018 Feb;44(1):60-69. doi: 10.1055/s-0037-1603937. Epub 2017 Sep 12. Review.

18.

Generation and characterization of aptamers targeting factor XIa.

Woodruff RS, Ivanov I, Verhamme IM, Sun MF, Gailani D, Sullenger BA.

Thromb Res. 2017 Aug;156:134-141. doi: 10.1016/j.thromres.2017.06.015. Epub 2017 Jun 9.

19.

Single-chain factor XII: a new form of activated factor XII.

Ivanov I, Matafonov A, Gailani D.

Curr Opin Hematol. 2017 Sep;24(5):411-418. doi: 10.1097/MOH.0000000000000363. Review.

20.

Making thrombolysis safer in stroke.

Gailani D.

Blood. 2017 Apr 20;129(16):2212-2213. doi: 10.1182/blood-2017-02-765610. No abstract available.

21.

Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen.

Ivanov I, Shakhawat R, Sun MF, Dickeson SK, Puy C, McCarty OJ, Gruber A, Matafonov A, Gailani D.

Thromb Haemost. 2017 Apr 3;117(4):671-681. doi: 10.1160/TH16-09-0691. Epub 2017 Jan 26.

22.

Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation.

Ivanov I, Matafonov A, Sun MF, Cheng Q, Dickeson SK, Verhamme IM, Emsley J, Gailani D.

Blood. 2017 Mar 16;129(11):1527-1537. doi: 10.1182/blood-2016-10-744110. Epub 2017 Jan 9.

23.

Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI.

Puy C, Tucker EI, Ivanov IS, Gailani D, Smith SA, Morrissey JH, Gruber A, McCarty OJ.

PLoS One. 2016 Oct 20;11(10):e0165172. doi: 10.1371/journal.pone.0165172. eCollection 2016.

24.

The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Wheeler AP, Gailani D.

Hematol Oncol Clin North Am. 2016 Oct;30(5):1099-114. doi: 10.1016/j.hoc.2016.05.007. Review.

25.

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.

Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, Richardson PG, Moslehi J.

JAMA Oncol. 2017 Jul 1;3(7):980-988. doi: 10.1001/jamaoncol.2016.3350. Review.

PMID:
27632640
26.

Why factor XI deficiency is a clinical concern.

Wheeler AP, Gailani D.

Expert Rev Hematol. 2016 Jul;9(7):629-37. doi: 10.1080/17474086.2016.1191944. Epub 2016 Jun 24. Review.

27.

Factor XI as a Therapeutic Target.

Gailani D, Gruber A.

Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1316-22. doi: 10.1161/ATVBAHA.116.306925. Epub 2016 May 12. Review.

28.

Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice.

Bane CE Jr, Ivanov I, Matafonov A, Boyd KL, Cheng Q, Sherwood ER, Tucker EI, Smiley ST, McCarty OJ, Gruber A, Gailani D.

PLoS One. 2016 Apr 5;11(4):e0152968. doi: 10.1371/journal.pone.0152968. eCollection 2016.

29.

A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.

Kokoye Y, Ivanov I, Cheng Q, Matafonov A, Dickeson SK, Mason S, Sexton DJ, Renné T, McCrae K, Feener EP, Gailani D.

Thromb Res. 2016 Apr;140:118-124. doi: 10.1016/j.thromres.2016.02.020. Epub 2016 Feb 18.

30.

Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice.

Shnerb Ganor R, Harats D, Schiby G, Gailani D, Levkovitz H, Avivi C, Tamarin I, Shaish A, Salomon O.

Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):475-81. doi: 10.1161/ATVBAHA.115.306954. Epub 2016 Jan 21.

31.

Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow.

Zilberman-Rudenko J, Itakura A, Wiesenekker CP, Vetter R, Maas C, Gailani D, Tucker EI, Gruber A, Gerdes C, McCarty OJ.

Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):510-7. doi: 10.1161/ATVBAHA.115.307034. Epub 2016 Jan 14.

32.

Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.

Mehta AY, Mohammed BM, Martin EJ, Brophy DF, Gailani D, Desai UR.

J Thromb Haemost. 2016 Apr;14(4):828-38. doi: 10.1111/jth.13254. Epub 2016 Feb 16.

33.

Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS).

ten Cate-Hoek AJ, Weitz JI, Gailani D, Meijer K, Philippou H, Bouman AC, Whitney Cheung Y, van Mens TE, Govers-Riemslag JW, Vries M, Bleker S, Biedermann JS, Stoof SC, Buller HR.

Thromb Res. 2015 Sep;136 Suppl 1:S13-8. doi: 10.1016/j.thromres.2015.07.036. No abstract available.

34.

Factor XI and contact activation as targets for antithrombotic therapy.

Gailani D, Bane CE, Gruber A.

J Thromb Haemost. 2015 Aug;13(8):1383-95. doi: 10.1111/jth.13005. Epub 2015 Jun 16. Review.

35.

Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.

Al-Horani RA, Gailani D, Desai UR.

Thromb Res. 2015 Aug;136(2):379-87. doi: 10.1016/j.thromres.2015.04.017. Epub 2015 Apr 22.

36.

Haemophilia A carriers experience reduced health-related quality of life.

Gilbert L, Paroskie A, Gailani D, Debaun MR, Sidonio RF.

Haemophilia. 2015 Nov;21(6):761-5. doi: 10.1111/hae.12690. Epub 2015 Apr 30.

37.

Factor XI antisense oligonucleotide for venous thrombosis.

Büller HR, Gailani D, Weitz JI.

N Engl J Med. 2015 Apr 23;372(17):1672. doi: 10.1056/NEJMc1503223. No abstract available.

PMID:
25901434
38.

A cross-sectional study of bleeding phenotype in haemophilia A carriers.

Paroskie A, Gailani D, DeBaun MR, Sidonio RF Jr.

Br J Haematol. 2015 Jul;170(2):223-8. doi: 10.1111/bjh.13423. Epub 2015 Apr 1.

39.

Future prospects for contact factors as therapeutic targets.

Gailani D.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):52-9. doi: 10.1182/asheducation-2014.1.52. Epub 2014 Nov 18. Review.

40.

Excess of heme induces tissue factor-dependent activation of coagulation in mice.

Sparkenbaugh EM, Chantrathammachart P, Wang S, Jonas W, Kirchhofer D, Gailani D, Gruber A, Kasthuri R, Key NS, Mackman N, Pawlinski R.

Haematologica. 2015 Mar;100(3):308-14. doi: 10.3324/haematol.2014.114728. Epub 2015 Jan 16.

41.

Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor.

Puy C, Tucker EI, Matafonov A, Cheng Q, Zientek KD, Gailani D, Gruber A, McCarty OJ.

Blood. 2015 Feb 26;125(9):1488-96. doi: 10.1182/blood-2014-10-604587. Epub 2015 Jan 13.

42.

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI; FXI-ASO TKA Investigators.

N Engl J Med. 2015 Jan 15;372(3):232-40. doi: 10.1056/NEJMoa1405760. Epub 2014 Dec 7.

43.

Development of anti-factor XIII antibodies in a patient with hereditary factor XIII deficiency receiving therapy for chronic hepatitis C.

Sosa R, Gailani D, Neff AT.

Haemophilia. 2014 Nov;20(6):e429-32. doi: 10.1111/hae.12537. Epub 2014 Oct 21. No abstract available.

PMID:
25333572
44.

Murine models in the evaluation of heparan sulfate-based anticoagulants.

Gailani D, Cheng Q, Ivanov IS.

Methods Mol Biol. 2015;1229:483-96. doi: 10.1007/978-1-4939-1714-3_37.

45.

Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor).

Wang J, Matafonov A, Madkhali H, Mahdi F, Watson D, Schmaier AH, Gailani D, Shariat-Madar Z.

Curr Mol Med. 2014;14(9):1173-85.

46.

Haemophilia A carriers demonstrate pathological and radiological evidence of structural joint changes.

Gilbert L, Rollins L, Hilmes M, Luo Y, Gailani D, Debaun MR, Sidonio RF.

Haemophilia. 2014 Nov;20(6):e426-9. doi: 10.1111/hae.12535. Epub 2014 Sep 23. No abstract available.

47.

Immediate recovery of acquired von Willebrand syndrome after left ventricular assist device explantation: implications for heart transplantation.

Davis ME, Haglund NA, Tricarico NM, Matafonov A, Gailani D, Maltais S.

ASAIO J. 2015 Jan-Feb;61(1):e1-4. doi: 10.1097/MAT.0000000000000157.

PMID:
25251586
48.

Factor XI as a target for antithrombotic therapy.

Bane CE Jr, Gailani D.

Drug Discov Today. 2014 Sep;19(9):1454-8. doi: 10.1016/j.drudis.2014.05.018. Epub 2014 Jun 2. Review.

49.

The mechanism underlying activation of factor IX by factor XIa.

Gailani D, Geng Y, Verhamme I, Sun MF, Bajaj SP, Messer A, Emsley J.

Thromb Res. 2014 May;133 Suppl 1:S48-51. doi: 10.1016/j.thromres.2014.03.020. Review.

50.

Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, Cheng Q, Sun MF, McCarty OJ, Tucker EI, Kataoka H, Renné T, Morrissey JH, Gruber A, Gailani D.

Blood. 2014 Mar 13;123(11):1739-46. doi: 10.1182/blood-2013-04-499111. Epub 2014 Jan 9.

Supplemental Content

Loading ...
Support Center